克林达米辛衍生物:揭示了作为潜在抗瘤剂的新前景
Yiduo Jia1, Yinmeng Zhang1, Hong Zhu1
1School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430079, China.
Pharmaceuticals (Basel, Switzerland)
|March 28, 2024
概括
新的克林达米辛衍生物通过向G蛋白结合受体和上腺素受体β来显示抗瘤潜力. 化合物3表现出显著的抗HepG2细胞活性,这表明癌症治疗的新疗法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- 克林达米辛衍生物正在研究它们的治疗潜力.
- 识别新的抗瘤标对于药物开发至关重要.
- 在分子层面上了解药物向相互作用是必不可少的.
研究的目的:
- 调查克林达米辛衍生物的抗瘤潜力,特别是化合物3和3e.
- 识别和描述这些化合物的分子标.
- 评估化合物3和3e的体外抗HepG2细胞活性.
主要方法:
- 对200个与克林达米辛相关的查目标进行了查.
- 分子动力学模拟以确定药物向相互作用.
- 测量MTT测试以评估抗HepG2细胞活性.
主要成果:
- 家庭A G蛋白结合受体被确定为一个关键的抗瘤标.
- 化合物3通过稳定的键显示出对特定蛋白质的高亲和力.
- 化合物3表现出显著的抗HepG2细胞活性,与5-甲可比.
结论:
- 克林达米辛衍生物,特别是化合物3,显示出作为抗瘤剂的前景.
- 上腺素受体β是调节免疫反应的化合物3的潜在目标.
- 这些发现为开发新型癌症疗法开辟了新的途径.
更多相关视频
相关概念视频
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
281
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
281
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
200
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
200


